| Literature DB >> 29651113 |
Katsushige Inada1, Yasushi Okoshi2,3, Yukiko Cho-Isoda4, Shingo Ishiguro4, Hisashi Suzuki3,5, Akinori Oki3,6, Yoshio Tamaki3,7, Toru Shimazui3,8, Hitoaki Saito9, Mitsuo Hori2, Tatsuo Iijima9, Hiroshi Kojima3,4.
Abstract
Lymph node metastasis is one of the most important factors for tumor dissemination. Quantifying microRNA (miRNA) expression using real-time PCR in formalin-fixed, paraffin-embedded (FFPE) lymph node can provide valuable information regarding the biological research for cancer metastasis. However, a universal endogenous reference gene has not been identified in FFPE lymph node. This study aimed to identify suitable endogenous reference genes for miRNA expression analysis in FFPE lymph node. FFPE lymph nodes were obtained from 41 metastatic cancer and from 16 non-cancerous tissues. We selected 10 miRNAs as endogenous reference gene candidates using the global mean method. The stability of candidate genes was assessed by the following four statistical tools: BestKeeper, geNorm, NormFinder, and the comparative ΔCt method. miR-103a was the most stable gene among candidate genes. However, the use of a single miR-103a was not recommended because its stability value exceeded the reference value. Thus, we combined stable genes and investigated the stability and the effect of gene normalization. The combination of miR-24, miR-103a, and let-7a was identified as one of the most stable sets of endogenous reference genes for normalization in FFPE lymph node. This study may provide a basis for miRNA expression analysis in FFPE lymph node tissue.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29651113 PMCID: PMC5897550 DOI: 10.1038/s41598-018-24338-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The small RNAs used in this study.
| Gene name | SD (ΔCtGlo) | Gene name | SD (ΔCtGlo) | Gene name | SD (ΔCtGlo) | No. |
|---|---|---|---|---|---|---|
| hsa-miR-191-5p† | 0.67* | hsa-let-7a-5p† | 0.84* | hsa-miR-193b-3p† | 1.09 | 0 |
| hsa-miR-24-3p† | 0.68* | hsa-miR-34a-5p† | 0.84* | hsa-miR-423-5p† | 1.10 | |
| hsa-miR-152-3p† | 0.72* | hsa-miR-21-5p† | 0.95* | hsa-miR-29c-3p† | 1.12 | |
| hsa-miR-148b-3p† | 0.73* | hsa-miR-16-5p† | 0.98* | hsa-let-7e-5p† | 1.16 | |
| hsa-miR-103a-3p† | 0.79* | hsa-miR-29b-3p† | 1.05 | SNORD44† | 1.19 | |
| hsa-miR-92a-3p† | 0.82* | hsa-miR-92b-3p† | 1.05 | |||
| hsa-let-7i-5p† | 0.69 | hsa-miR-193a-3p† | 1.06 | hsa-miR-145-5p† | 1.81 | 1 |
| hsa-miR-181b-5p† | 0.70 | hsa-miR-29a-3p† | 1.07 | hsa-miR-135a-5p† | 1.83 | |
| hsa-miR-106b-5p† | 0.76 | hsa-miR-214-3p† | 1.22 | hsa-miR-31-5p† | 1.84 | |
| hsa-miR-345-5p† | 0.86 | hsa-miR-130a-3p† | 1.36 | hsa-miR-192-5p† | 1.91 | |
| hsa-miR-27b-3p† | 0.94 | hsa-miR-363-3p† | 1.36 | hsa-miR-194-5p† | 1.92 | |
| hsa-miR-99a-5p† | 0.98 | hsa-miR-142-3p† | 1.55 | hsa-miR-210-3p† | 1.95 | |
| hsa-miR-132-3p† | 1.03 | hsa-miR-181a-5p† | 1.60 | |||
| SNORD48† | 1.06 | hsa-miR-146a-5p† | 1.65 | |||
| hsa-miR-19b-3p† | 0.97 | U6 snRNA† | 1.84 | hsa-miR-155-5p† | 1.24 | ≥2 |
| hsa-miR-10b-5p† | 1.50 | hsa-miR-138-5p† | 2.08 | hsa-miR-148a-3p† | 1.30 | |
| hsa-miR-196a-5p† | 2.69 | hsa-miR-141-3p† | 3.52 | hsa-miR-10a-5p† | 1.35 | |
| hsa-miR-200c-3p† | 3.39 | hsa-miR-27a-3p† | 1.09 | hsa-miR-182-5p† | 2.25 | |
| hsa-miR-153-3p | 1.49 | hsa-miR-592 | 2.22 | hsa-miR-122-5p | 2.60 | ≥6 |
| hsa-miR-372-3p | 1.57 | hsa-miR-124-3p | 2.30 | hsa-miR-509-3p | 2.68 | |
| hsa-miR-204-5p | 1.62 | hsa-miR-187-3p | 2.33 | hsa-miR-200a-3p | 2.96 | |
| hsa-miR-572 | 1.84 | hsa-miR-373-3p | 2.36 | hsa-miR-211-5p | 3.02 | |
| hsa-miR-552-3p | 1.89 | hsa-miR-34b-5p | 2.36 | hsa-miR-375 | 3.76 | |
| hsa-miR-382-5p | 1.98 | hsa-miR-9-3p | 2.38 | hsa-miR-205-5p | 5.12 | |
| hsa-miR-616-3p | 2.00 | hsa-miR-514a-3p | 2.56 |
No.: number of undetected samples; SD: standard deviation. †These 51 genes were used to calculate the global mean. *These 10 genes were selected as candidate reference genes.
Figure 1The threshold cycle (Ct) value of qRT-PCR for candidate reference genes in each sample type. These samples were formalin-fixed, paraffin-embedded lymph node tissues from non-cancerous (Cont.) and metastatic cancer tissues (Breast, Colon, Lung, Ovary, Pancreas, Stomach, and Other represent the location of primary tumor). The dot plots represents the raw Ct values of reference gene candidates.
Descriptive statistics obtained by BestKeeper analysis.
| Gene | miR-21 | miR-16 | miR-148b | miR-92a | miR-34a | miR-191 | miR-152 | let-7a | miR-24 | miR-103a | BKI (n = 10) | BKI (n = 7) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 |
| GM [Ct] | 22.733 | 23.492 | 29.789 | 26.157 | 27.999 | 27.741 | 29.281 | 24.124 | 25.017 | 26.058 | 26.138 | 26.573 |
| AM [Ct] | 22.786 | 23.543 | 29.825 | 26.182 | 28.026 | 27.762 | 29.311 | 24.170 | 25.059 | 26.102 | 26.165 | 26.598 |
| Min [Ct] | 18.592 | 19.075 | 26.276 | 22.905 | 25.543 | 24.954 | 27.126 | 21.330 | 22.417 | 23.362 | 23.983 | 24.757 |
| Max [Ct] | 27.486 | 29.219 | 34.338 | 28.479 | 31.928 | 30.182 | 33.021 | 30.964 | 30.615 | 32.121 | 30.087 | 30.484 |
| SD [±Ct] | 1.197 | 1.074 | 1.099 | 0.846 | 0.981 | 0.831 | 1.019 | 1.035 | 1.020 | 1.005 | 0.869 | 0.821 |
| CV [%Ct] | 5.255 | 4.562 | 3.685 | 3.231 | 3.500 | 2.994 | 3.478 | 4.280 | 4.070 | 3.852 | 3.320 | 3.086 |
| r with BKI (n = 10) | 0.830* | 0.863* | 0.914* | 0.751* | 0.785* | 0.820* | 0.842* | 0.899* | 0.929* | 0.961* | — | — |
| r with BKI (n = 7) | — | — | — | 0.745* | 0.780* | 0.801* | 0.854* | 0.923* | 0.942* | 0.963* | — | — |
| Ranking | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | — | — |
AM: arithmetic; BKI: BestKeeper Index; Ct: threshold cycle value; CV: coefficient of variation; GM: geometric; Max: maximum value; Min: minimum value; N: number of available samples; n: number of genes; r: Pearson correlation coefficient; SD: standard deviation; *p ≤ 0.001, P-value associated with the Pearson correlation coefficient. BKI was calculated for 10 genes and for seven genes, excluding the gene with the highest standard deviation.
Figure 2Stability analysis using geNorm, NormFinder, and the comparative ΔCt method. (a) The average gene expression stability (M value) and the pairwise variation value (V value) calculated by geNorm. (b) The inter- and intra-group variability and stability values estimated using NormFinder. In the variability graph, the error bars represent the average of the intra-group variability and the boxes indicate the confidence interval for the inter-group variability. (c) Mean standard deviation (Mean SD) was calculated by the comparative ΔCt method performing pairwise comparisons between genes (ΔCtPair).
Calculation of the overall stability according to the four stability analyses used in this study.
| Rank | Gene | Overall Ranking | BestKeeper | geNorm | NormFinder | Comparative ΔCtPair |
|---|---|---|---|---|---|---|
| r with BKI (Ranking) | M value (Ranking) | Stability value (Ranking) | Mean SD (Ranking) | |||
| 1 | miR-103a | 1.0 | 0.963 (1) | 0.699 (1) | 0.114 (1) | 0.931 (1) |
| 2 | miR-24 | 1.9 | 0.942 (2) | 0.699 (1) | 0.120 (3) | 0.966 (2) |
| 3 | let-7a | 3.7 | 0.923 (3) | 0.757 (3) | 0.150 (5) | 1.053 (4) |
| 4 | miR-191 | 4.3 | 0.801 (5) | 0.975 (7) | 0.119 (2) | 1.066 (5) |
| 5 | miR-148b | 4.9 | −(8) | 0.810 (4) | 0.177 (6) | 1.000 (3) |
| 6 | miR-152 | 5.6 | 0.854 (4) | 0.882 (5) | 0.188 (8) | 1.071 (6) |
| 7 | miR-92a | 6.7 | 0.745 (7) | 1.012 (8) | 0.149 (4) | 1.170 (9) |
| 8 | miR-34a | 7.2 | 0.780 (6) | 1.042 (9) | 0.185 (7) | 1.128 (7) |
| 9 | miR-16 | 7.9 | −(9) | 0.933 (6) | 0.226 (9) | 1.147 (8) |
| 10 | miR-21 | 10.0 | −(10) | 1.073 (10) | 0.233 (10) | 1.197 (10) |
BKI: BestKeeper Index, calculated for seven genes; SD: standard deviation.
Descriptive statistics for combined genes obtained by BestKeeper analysis.
| Gene | U6/SNORD44/SNORD48 | miR-16 | miR-191 | miR-16/miR-345 | miR-148b/miR-152 | Global mean | miR-16/let-7a | miR-24/miR-103a | miR-24/miR-103a/let-7a | BKI (n = 9) | BKI (n = 7) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 | 57 |
| GM [Ct] | 28.048 | 23.492 | 27.741 | 26.638 | 29.540 | 28.658 | 23.813 | 25.540 | 25.070 | 26.426 | 26.647 |
| AM [Ct] | 28.094 | 23.543 | 27.762 | 26.670 | 29.568 | 28.678 | 23.856 | 25.581 | 25.110 | 26.455 | 26.674 |
| Min [Ct] | 24.824 | 19.075 | 24.954 | 22.945 | 27.445 | 26.577 | 20.613 | 23.162 | 22.905 | 24.400 | 24.700 |
| Max [Ct] | 32.169 | 29.219 | 30.182 | 30.726 | 33.680 | 31.885 | 29.628 | 31.368 | 30.848 | 30.718 | 30.889 |
| SD [±Ct] | 1.277 | 1.074 | 0.831 | 0.931 | 0.954 | 0.822 | 1.015 | 0.987 | 0.971 | 0.889 | 0.872 |
| CV [%Ct] | 4.545 | 4.562 | 2.994 | 3.490 | 3.226 | 2.866 | 4.255 | 3.857 | 3.867 | 3.360 | 3.269 |
| r with BKI (n = 9) | 0.757* | 0.910* | 0.799* | 0.899* | 0.931* | 0.951* | 0.962* | 0.968* | 0.972* | — | — |
| r with BKI (n = 7) | — | — | 0.808* | 0.897* | 0.947* | 0.955* | 0.958* | 0.975* | 0.981* | — | — |
| Ranking | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | — | — |
AM: arithmetic; BKI: BestKeeper Index; Ct: threshold cycle value; CV: coefficient of variation; GM: geometric; Max: maximum value; Min: minimum value; N: number of available samples; n: number of factors; r: Pearson correlation coefficient; SD: standard deviation; *p ≤ 0.001, P-value associated with the Pearson correlation coefficient. BKI was calculated for 9 factors and for seven factors, excluding the gene with the highest standard deviation.
Figure 3Expression stability of endogenous reference gene candidates determined by geNorm, NormFinder, and the comparative ΔCtPair method. (a) The M values and V values calculated by geNorm. (b) The inter- (box) and intra- (error bars) group variability and stability values determined using NormFinder. (c) Mean standard deviation (Mean SD) was calculated by the comparative ΔCtPair method.
Stability ranking of the endogenous reference gene candidates.
| Rank | Gene | Overall Ranking | BestKeeper | geNorm | NormFinder | Comparative ΔCtPair |
|---|---|---|---|---|---|---|
| r with BKI (Ranking) | M value (Ranking) | Stability value (Ranking) | Mean SD (Ranking) | |||
| 1 | miR-24/miR-103a/let-7a | 1.3 | 0.981 (1) | 0.235 (1) | 0.095 (3) | 0.721 (1) |
| 2 | miR-24/miR-103a | 2.0 | 0.975 (2) | 0.235 (1) | 0.096 (4) | 0.742 (2) |
| 3 | miR-148b/miR-152 | 2.9 | 0.947 (5) | 0.448 (3) | 0.094 (1) | 0.785 (5) |
| 4 | Global mean | 4.1 | 0.955 (4) | 0.515 (4) | 0.108 (6) | 0.750 (3) |
| 5 | miR-16/let-7a | 4.2 | 0.958 (3) | 0.572 (5) | 0.104 (5) | 0.771 (4) |
| 6 | miR-16/miR-345 | 4.6 | 0.897 (6) | 0.639 (6) | 0.094 (2) | 0.882 (6) |
| 7 | miR-16 | 7.5 | −(8) | 0.694 (7) | 0.147 (8) | 0.958 (7) |
| 8 | miR-191 | 7.5 | 0.808 (7) | 0.763 (8) | 0.124 (7) | 1.016 (8) |
| 9 | U6/SNORD44/SNORD48 | 9.0 | −(9) | 0.879 (9) | 0.179 (9) | 1.282 (9) |
BKI: BestKeeper Index; SD: standard deviation.
Figure 4Effect of normalization on the expression of miR-29c in formalin-fixed, paraffin-embedded lymph node tissue. Relative expression of a metastatic lymph node (Colon: n = 5) was compared with a lymph node without cancer (Cont.: n = 16). The expression levels (2−ΔCt) of miR-29c are shown as box plots (log2 scale on the y-axis). The median is represented as a horizontal line within each box and its lower and upper edges represent the 25–75 percentile region. The whiskers represent the 10–90 percentile region, and the dots represent the outliers. Statistically significant differences were determined using the Mann–Whitney U test (two-tailed test).
Characteristics of the samples.
| Sample Group | Location of | N | Mean age | Subtype (N) |
|---|---|---|---|---|
| Metastatic LN | Breast | 5 | 58 | Invasive carcinoma (5) |
| (5; 0) | (41–81) | |||
| Colon | 5 | 68.6 | Adenocarcinoma (5) | |
| (1; 4) | (56–75) | |||
| Lung | 5 | 66.4 | Small cell carcinoma (1), Squamous cell carcinoma (1), Adenocarcinoma (3) | |
| (4; 1) | (57–76) | |||
| Ovary | 3 | 69.3 | Squamous cell carcinoma (1), Adenocarcinoma (2) | |
| (3; 0) | (65–76) | |||
| Pancreas | 8 | 67.1 | Carcinoma (1), Adenocarcinoma (7) | |
| (2; 6) | (57–77) | |||
| Stomach | 5 | 69.8 | Adenocarcinoma (5) | |
| (2; 3) | (62–79) | |||
| Other | 10 | 75.4 | Carcinoma (not specified) (3), Small cell carcinoma (1), Squamous cell carcinoma (1), Adenocarcinoma (3), Melanoma (2) | |
| (5; 5) | (58–90) | |||
| Total | 41 | 69 | Carcinoma (9), Small cell carcinoma (2), Squamous cell carcinoma (3), Adenocarcinoma (25), Melanoma (2) | |
| (22; 19) | (36–90) | |||
| Non-cancerous LN | — | 16 | 76 | Reactive LN without any tumor cells (16) |
| (8; 8) | (51–83) |
F: female; LN: lymph node; M: male; N: number of samples; “Other” includes endometrial, thyroid, esophagus, and prostate cancers; cholangiocellular carcinoma; and malignant melanoma. The non-cancerous samples were mainly obtained from lymph node dissection and without any findings of cancer metastasis at histological analysis. They are from patients with lung cancer (5), bile duct cancer (3), endometrial cancer (2), colon cancer (1), hypopharynx cancer (1), malignant melanoma (1), parotid cancer (1), stomach cancer (1), and reactive mesenteric lymph node of ulcer of the small intestine (1).